Neutropenia is a big issue too. Are you going to have patients on Neupogen and hypertension drug while taking R788? Its still not clear how the drug causes hypertension. If you don't understand the MOA, other unknown AE will pop up in the long run. You can argue that 90% of patients will be eligible for the treatment. However, FDA is now extremely anal on drugs designed for chronic use after viox, I just don't think RIGL will get a good deal in RA unless they do a 2 or 3 yea trials studying the long term effect of R788. Again I might just be biased since ARNA's Lorcaserin can not get a partnership even with positive phase 3 data.
Market Data 
Markets 
AI
